» Articles » PMID: 24065402

Antiemetic Guideline Consistency and Incidence of Chemotherapy-induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study

Overview
Journal J Oncol Pract
Specialty Oncology
Date 2013 Sep 26
PMID 24065402
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Consensus guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) are variably implemented in practice. The purpose of this study was to evaluate the impact of guideline-consistent/guideline-inconsistent CINV prophylaxis (GCCP/GICP) on the incidence of no CINV after cycle 1 of highly or moderately emetogenic chemotherapy (HEC or MEC).

Patients And Methods: This prospective observational study enrolled chemotherapy-naive adult outpatients who received single-day HEC or MEC at four oncology practice networks, all using electronic health record (EHR) systems, in Georgia, Tennessee, and Florida. Results from the Multinational Association of Supportive Care in Cancer Antiemesis Tool, a validated tool to measure CINV, administered 5 to 8 days postchemotherapy, were merged with EHR data. The primary end point, no CINV, defined as no emesis and no clinically significant nausea (score < 3 on 0-10 scale), was compared between cohorts using logistic regression.

Results: A total of 1,295 patients were enrolled (mean age, 59.3 years; 70.0% female; 35.5% HEC). The overall prevalence of GCCP was 57.3%. When corticosteroids were prescribed on days 2 to 4 after all HEC, GCCP for HEC increased from 28.7% to 89.8%; when NK1-receptor antagonists were prescribed after all MEC, GCCP for MEC increased from 73.1% to 97.8%. Over 5 days postchemotherapy, the incidence of no CINV was significantly higher in the GCCP cohort than the GICP cohort (53.4% v 43.8%; P < .001). The adjusted odds of no CINV with GCCP was 1.31 (95% CI, 1.07 to 1.69; P = .037).

Conclusion: Increased adherence to antiemetic guidelines could significantly reduce the incidence of CINV after HEC and MEC.

Citing Articles

Pharmacist intervention and identification of adverse events related to treatment efficacy in cancer chemotherapy to improve clinical outcomes.

Fujii H J Pharm Health Care Sci. 2024; 10(1):81.

PMID: 39696667 PMC: 11658043. DOI: 10.1186/s40780-024-00403-4.


The evolving landscape of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: inspiration from cisplatin-based antiemetic and non-antiemetic trials.

Sun Y, Wang Y, Chen G, Zhang Y, Zhang L, Chen X Support Care Cancer. 2024; 32(12):822.

PMID: 39589545 PMC: 11599296. DOI: 10.1007/s00520-024-09035-8.


Clinical practice guideline-inconsistent chemotherapy-induced vomiting prophylaxis in pediatric cancer patients in community settings: A Children's Oncology Group study.

Sugalski A, Grimes A, Nuno M, Ramakrishnan S, Beauchemin M, Robinson P Pediatr Blood Cancer. 2024; 71(11):e31295.

PMID: 39238137 PMC: 11464177. DOI: 10.1002/pbc.31295.


Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.

Grimison P, Mersiades A, Kirby A, Tognela A, Olver I, Morton R J Clin Oncol. 2024; 42(34):4040-4050.

PMID: 39151115 PMC: 11608591. DOI: 10.1200/JCO.23.01836.


.

Choquette A, Sivananthan A, Guillemette A, OShaubhnessy E, Pinheiro-Maltez M, MacKeigan L Can Oncol Nurs J. 2024; 31(1):73-82.

PMID: 38919461 PMC: 11195566. DOI: 10.5737/236880763117382.